|
The staff of Dermatology Times wishes you a joyous and safe holiday season. In this week's newsletter, check out what some industry experts consider the most clinically relevant advances from the past year. Then be sure to review our collection of the most-read articles from 2013, and see if there is anything you might have missed.
|
THE YEAR IN REVIEW
As 2013 came to a close, Dermatology Times asked some of its editorial advisory board members what they considered to be some of the most clinically relevant advances in the past year. » More
|
TOP-READ STORIES OF 2013
Sun exposure may help to reduce blood pressure, demonstrating that the benefits of exposure to UV rays may be greater than the risk of getting skin cancer, according to a proof-of-principle study. » More
|
|
Having reached the end of a 10-month injunction barring it from selling its botulinum toxin product in the U.S., Merz is once again launching Xeomin for the treatment of glabellar lines. » More
|
|
A dermatology researcher from Case Western Reserve University, Cleveland, has been awarded $1.9 million to conduct studies related to psoriasis. » More
|
|
The Food and Drug Administration has granted 510(k) clearance to Nucletron for Esteya, an electronic brachytherapy system for high-precision skin cancer treatment. » More
|
|
Technology in devices being used for airport security could lead to the development of more advanced skin cancer screening, recent research suggests. » More
|
|
For many physicians, no matter their specialty, the one thing that keeps them up at night is fear of medical malpractice lawsuits. Elisabeth Madden, partner at Lynch, Gilardi & Grummer law firm in San Francisco, outlines the top ways to avoid these malpractice suits. » More
|
|
The decision to relinquish control and add a nurse injector to your cosmetic surgery staff can be a hard one, but there are more pros than cons, says Edwin Williams, M.D., who spoke at the Vegas Cosmetic Surgery and Aesthetic Dermatology meeting. » More
|
|
Some diseases, conditions and treatments are different in patients with skin of color as compared to Caucasian patients, and understanding these differences is essential in choosing appropriate therapy, according to Heather Woolery-Lloyd, M.D.
» More
|
|
A newly launched diagnostic test by Myriad Genetics may differentiate malignant melanoma from benign skin lesions. » More
|
|
|
Like
Tweet
